Inactive Instrument

Press Releases CEL-SCI Corporation Nyse

Equities

US1508374097

End-of-day quote Nyse Other stock markets
- ^USD	-

May. 08	Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	MT
May. 08	CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cel-Sci: Fiscal Q2 Earnings Snapshot	May. 16	AQ
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results	May. 16	BU
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer	May. 09	AQ
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	May. 08	BU
CEL-SCI Appoints Mario Gobbo to Its Board of Directors	Apr. 23	BU
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology	Mar. 19	BU
CEL-SCI Corporation Issues Letter to Shareholders	Mar. 06	BU
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results	Feb. 15	BU
Cel-Sci: Fiscal Q1 Earnings Snapshot	Feb. 14	AQ
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock	Feb. 13	BU
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	Feb. 12	AQ
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock	Feb. 09	BU
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head and Neck Cancer Drug	Feb. 07	AQ
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug	Feb. 06	BU
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path towards Marketing Authorization for Multikine	Feb. 01	AQ
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®	Jan. 31	BU
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments	Dec. 22	BU
UK'S National Institute for Health and Care Excellence Selects CEL-SCI's Multikine as Potential New Standard of Care for Head and Neck Cancer	Dec. 05	AQ
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer	Dec. 04	BU
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock	Nov. 20	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases CEL-SCI Corporation Nyse

Equities

US1508374097

Press Releases

Filters